PMID- 15213333
OWN - NLM
STAT- MEDLINE
DCOM- 20041101
LR  - 20121115
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 43
IP  - 9
DP  - 2004 Sep
TI  - Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in 
      MRL/lpr mice.
PG  - 1121-8
AB  - OBJECTIVE: Monocyte chemoattractant protein-1 (MCP-1) is up-regulated and 
      recruits and activates inflammatory cells in human diffuse proliferative lupus 
      nephritis (DPLN) and in nephritis of lupus model MRL/lpr mice. The aim of this 
      study was to examine whether anti-MCP-1 gene therapy inhibits the progression of 
      nephritis in MRL/lpr mice. METHOD: An NH(2)-terminal deletion mutant of the MCP-1 
      gene, 7ND, was injected into skeletal muscles of MRL/lpr mice with advanced stage 
      nephritis to blockade MCP-1 and its receptor (CCR2) signalling pathway. RESULT: 
      Histological findings of kidneys in treated mice, which received more than four 
      injections of 7ND, showed that protection against renal injury resulted from 
      reduced infiltration of leucocytes. Therefore, this therapy has been shown to 
      prolong the life span of MRL/lpr mice. CONCLUSION: Anti-MCP-1 gene therapy is 
      specifically effective in the localized inflammatory region. The data presented 
      here indicate that this anti-MCP-1 gene therapy may be effective adjunct in the 
      management of DPLN.
FAU - Shimizu, S
AU  - Shimizu S
AD  - Department of Medicine and Biosystemic Science, Graduate School of Medical 
      Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
FAU - Nakashima, H
AU  - Nakashima H
FAU - Masutani, K
AU  - Masutani K
FAU - Inoue, Y
AU  - Inoue Y
FAU - Miyake, K
AU  - Miyake K
FAU - Akahoshi, M
AU  - Akahoshi M
FAU - Tanaka, Y
AU  - Tanaka Y
FAU - Egashira, K
AU  - Egashira K
FAU - Hirakata, H
AU  - Hirakata H
FAU - Otsuka, T
AU  - Otsuka T
FAU - Harada, M
AU  - Harada M
LA  - eng
PT  - Journal Article
DEP - 20040622
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Ccr2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, CCR2)
RN  - 0 (Receptors, Chemokine)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Animals
MH  - Antibodies, Antinuclear/blood
MH  - Chemokine CCL2/biosynthesis/blood/*genetics
MH  - DNA/immunology
MH  - Genetic Therapy/*methods
MH  - Immunoglobulin G/analysis
MH  - Kidney/immunology/pathology
MH  - Leukocytes/immunology
MH  - Lung/immunology/pathology
MH  - Lupus Nephritis/genetics/pathology/*therapy
MH  - Lymphatic Diseases/genetics/pathology/therapy
MH  - Mice
MH  - Mice, Inbred MRL lpr
MH  - Muscle, Skeletal
MH  - Mutation
MH  - Proteinuria/immunology
MH  - Receptors, CCR2
MH  - Receptors, Chemokine/genetics
MH  - Signal Transduction/genetics
MH  - Splenomegaly/genetics/pathology/therapy
MH  - Transgenes/genetics
EDAT- 2004/06/24 05:00
MHDA- 2004/11/02 09:00
CRDT- 2004/06/24 05:00
PHST- 2004/06/24 05:00 [pubmed]
PHST- 2004/11/02 09:00 [medline]
PHST- 2004/06/24 05:00 [entrez]
AID - keh277 [pii]
AID - 10.1093/rheumatology/keh277 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2004 Sep;43(9):1121-8. doi: 10.1093/rheumatology/keh277. 
      Epub 2004 Jun 22.